新辅助化疗后乳腺癌的病理完整反应和相关因素:一项回顾性研究
Adnan Gündoğdu1, Mehmet Uluşahin1, Arif Burak Çekiç1
1Department of General Surgery, Karadeniz Technical University Faculty of Medicine, Trabzon, Türkiye.
Turkish journal of surgery
|July 22, 2024
概括
分子亚型是预测乳腺癌新辅助化疗 (NAC) 病理完整反应 (pCR) 的关键因素. HER2阳性和三阴性亚型的pCR率较高,指导了个性化治疗策略.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
- 临床病理学 临床病理学
背景情况:
- 新辅助化疗 (NAC) 是乳腺癌的关键治疗方法.
- 确定病理完整反应 (pCR) 的因素对于治疗优化至关重要.
- 了解pCR的预测因素可以改善患者的治疗结果,并定制治疗方法.
研究的目的:
- 在接受NAC.的乳腺癌患者中确定与pCR相关的临床和病理因素.
- 评估分子亚型对NAC反应的影响.
- 为了确定侵袭性乳腺癌治疗成功的预测因素.
主要方法:
- 对119名接受NAC.的女性乳腺癌患者 (年龄大于18岁) 的回顾性单中心研究.
- 收集的数据包括人口统计,临床,放射,治疗和病理信息.
- 使用多变量逻辑回归分析来确定与pCR相关的因素.
主要成果:
- 总体PCR率为27.7% (33/119名患者).
- 分子类型是pCR的唯一独立预测因子.
- 与光子亚型 (8.7%-10.8%) 相比,HER2阳性 (54.5%) 和三阴性 (46.7%) 的亚型中观察到更高的pCR率.
结论:
- 分子亚型是乳腺癌中pCR到NAC的重要决定因素.
- 在HER2阳性和三阴性乳腺癌中,对NAC的反应率更高.
- 这些发现强调了分子分析对乳腺癌个性化新辅助疗法的重要性.
相关概念视频
01:21Cancer Survival Analysis
336
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
336
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K